OBJECTIVE: We used a whole blood assay to characterize the immune system's response after cardiopulmonary bypass (CPB) in children to identify the risk for postoperative infections. We assessed the impact of CPB on histone methylation as a potential mechanism for altering gene expression necessary for the immune system's capacity to defend against infections. METHODS: We prospectively enrolled patients less than 18 years old undergoing heart surgery requiring CPB at C.S. Mott Children's Hospital. Blood was obtained from patients before CPB, on CPB, and on postoperative days 1, 3, and 5. Ex vivo lipopolysaccharide-induced tumor necrosis factor-alpha production measured the capacity of the immune system. Serum cytokines were measured using a multiplex assay. Chromatin immunoprecipitation to detect histone modifications at the interleukin (IL) 10 promoter was performed on circulating mononuclear cells from a subgroup of patients. RESULTS: We enrolled 92 patients, and postoperative day 1 samples identified a subpopulation of immunocompetent patients at low risk for infections with a specificity of 93% (confidence interval [CI], 83%-98%) and a negative predictive value of 88% (CI, 77%-95%; P = .006). Patients classified as immunoparalyzed had serum IL-10 levels 2.4-fold higher than the immunocompetent group (mean, 14.3 ± 18.3 pg/mL vs 6.0 ± 5.0 pg/mL; P = .01). In a subgroup of patients, we identified a greater percent of the "gene on" epigenetic signature, H3K4me3, associated with the IL-10 promoter after CPB. CONCLUSIONS: Our data demonstrate that immunophenotyping patients after CPB can predict their risk for the development of postoperative infections. Novel mechanistic data suggest that CPB affects epigenetic alterations in IL-10 gene regulation.
OBJECTIVE: We used a whole blood assay to characterize the immune system's response after cardiopulmonary bypass (CPB) in children to identify the risk for postoperative infections. We assessed the impact of CPB on histone methylation as a potential mechanism for altering gene expression necessary for the immune system's capacity to defend against infections. METHODS: We prospectively enrolled patients less than 18 years old undergoing heart surgery requiring CPB at C.S. Mott Children's Hospital. Blood was obtained from patients before CPB, on CPB, and on postoperative days 1, 3, and 5. Ex vivo lipopolysaccharide-induced tumor necrosis factor-alpha production measured the capacity of the immune system. Serum cytokines were measured using a multiplex assay. Chromatin immunoprecipitation to detect histone modifications at the interleukin (IL) 10 promoter was performed on circulating mononuclear cells from a subgroup of patients. RESULTS: We enrolled 92 patients, and postoperative day 1 samples identified a subpopulation of immunocompetent patients at low risk for infections with a specificity of 93% (confidence interval [CI], 83%-98%) and a negative predictive value of 88% (CI, 77%-95%; P = .006). Patients classified as immunoparalyzed had serum IL-10 levels 2.4-fold higher than the immunocompetent group (mean, 14.3 ± 18.3 pg/mL vs 6.0 ± 5.0 pg/mL; P = .01). In a subgroup of patients, we identified a greater percent of the "gene on" epigenetic signature, H3K4me3, associated with the IL-10 promoter after CPB. CONCLUSIONS: Our data demonstrate that immunophenotyping patients after CPB can predict their risk for the development of postoperative infections. Novel mechanistic data suggest that CPB affects epigenetic alterations in IL-10 gene regulation.
Authors: H D Volk; P Reinke; D Krausch; H Zuckermann; K Asadullah; J M Müller; W D Döcke; W J Kox Journal: Intensive Care Med Date: 1996-10 Impact factor: 17.440
Authors: Meredith L Allen; J Andreas Hoschtitzky; Mark J Peters; Martin Elliott; Allan Goldman; Ian James; Nigel J Klein Journal: Crit Care Med Date: 2006-10 Impact factor: 7.598
Authors: Guillaume Monneret; Alain Lepape; Nicolas Voirin; Julien Bohé; Fabienne Venet; Anne-Lise Debard; Hélène Thizy; Jacques Bienvenu; François Gueyffier; Philippe Vanhems Journal: Intensive Care Med Date: 2006-06-02 Impact factor: 17.440
Authors: Mark W Hall; Mikhail A Gavrilin; Nina L Knatz; Michelle D Duncan; Soledad A Fernandez; Mark D Wewers Journal: Pediatr Res Date: 2007-11 Impact factor: 3.756
Authors: Thomas P Shanley; Natalie Cvijanovich; Richard Lin; Geoffrey L Allen; Neal J Thomas; Allan Doctor; Meena Kalyanaraman; Nancy M Tofil; Scott Penfil; Marie Monaco; Kelli Odoms; Michael Barnes; Bhuvaneswari Sakthivel; Bruce J Aronow; Hector R Wong Journal: Mol Med Date: 2007 Sep-Oct Impact factor: 6.354
Authors: Mark W Hall; Kristin C Greathouse; Rajan K Thakkar; Eric A Sribnick; Jennifer A Muszynski Journal: Pediatr Clin North Am Date: 2017-08-18 Impact factor: 3.278
Authors: Tanya Novak; Mark W Hall; Douglas R McDonald; Margaret M Newhams; Anushay J Mistry; Angela Panoskaltsis-Mortari; Peter M Mourani; Laura L Loftis; Scott L Weiss; Keiko M Tarquinio; Barry Markovitz; Mary E Hartman; Adam Schwarz; Wolfgang G Junger; Adrienne G Randolph Journal: J Allergy Clin Immunol Date: 2020-02-06 Impact factor: 10.793
Authors: Joseph A Carcillo; Bradley Podd; Rajesh Aneja; Scott L Weiss; Mark W Hall; Timothy T Cornell; Thomas P Shanley; Lesley A Doughty; Trung C Nguyen Journal: Pediatr Crit Care Med Date: 2017-03 Impact factor: 3.624
Authors: Mark W Hall; Susan M Geyer; Chao-Yu Guo; Angela Panoskaltsis-Mortari; Philippe Jouvet; Jill Ferdinands; David K Shay; Jyotsna Nateri; Kristin Greathouse; Ryan Sullivan; Tram Tran; Shannon Keisling; Adrienne G Randolph Journal: Crit Care Med Date: 2013-01 Impact factor: 7.598
Authors: Cesar Mella; M Carmen Suarez-Arrabal; Santiago Lopez; Julie Stephens; Soledad Fernandez; Mark W Hall; Octavio Ramilo; Asuncion Mejias Journal: J Infect Dis Date: 2012-11-29 Impact factor: 5.226